Sandbox anthrax01: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(7 intermediate revisions by the same user not shown)
Line 1: Line 1:


<!--
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font></SMALL><ref>{{Cite journal | doi = 10.3201/eid2002.130687 | issn = 1080-6059 | volume = 20 | issue = 2 | last = Hendricks | first = Katherine A. | coauthors = Mary E. Wright, Sean V. Shadomy, John S. Bradley, Meredith G. Morrow, Andy T. Pavia, Ethan Rubinstein, Jon-Erik C. Holty, Nancy E. Messonnier, Theresa L. Smith, Nicki Pesik, Tracee A. Treadwell, William A. Bower, Workgroup on Anthrax Clinical Guidelines | title = Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults | journal = Emerging Infectious Diseases | date = 2014-02 | pmid = 24447897 | pmc = PMC3901462 }}</ref><ref>{{Cite journal | doi = 10.1542/peds.2014-0563 | issn = 1098-4275 | last = Bradley | first = John S. | coauthors = Georgina Peacock, Steven E. Krug, William A. Bower, Amanda C. Cohn, Dana Meaney-Delman, Andrew T. Pavia, AAP COMMITTEE ON INFECTIOUS DISEASES and DISASTER PREPAREDNESS ADVISORY COUNCIL | title = Pediatric Anthrax Clinical Management | journal = Pediatrics | date = 2014-04-28 | pmid = 24777226 }}</ref><ref>{{Cite journal | doi = 10.3201/eid2002.130611 | issn = 1080-6059 | volume = 20 | issue = 2 | last = Meaney-Delman | first = Dana | coauthors = Marianne E. Zotti, Andreea A. Creanga, Lara K. Misegades, Etobssie Wako, Tracee A. Treadwell, Nancy E. Messonnier, Denise J. Jamieson, Workgroup on Anthrax in Pregnant and Postpartum Women | title = Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women | journal = Emerging Infectious Diseases | date = 2014-02 | pmid = 24457117 | pmc = PMC3901460 }}</ref>
 
==Empiric Therapy <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''Lancet. 2012;380(9854):1693-702.''<ref name="van de Beek-2012">{{Cite journal | last1 = van de Beek | first1 = D. | last2 = Brouwer | first2 = MC. | last3 = Thwaites | first3 = GE. | last4 = Tunkel | first4 = AR. | title = Advances in treatment of bacterial meningitis. | journal = Lancet | volume = 380 | issue = 9854 | pages = 1693-702 | month = Nov | year = 2012 | doi = 10.1016/S0140-6736(12)61186-6 | PMID = 23141618 }}</ref> and ''Clin Infect Dis. 2004;39(9):1267-84.''<ref name="pmid15494903">Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM et al. (2004) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15494903 Practice guidelines for the management of bacterial meningitis.] ''Clin Infect Dis'' 39 (9):1267-84. [http://dx.doi.org/10.1086/425368 DOI:10.1086/425368] PMID: [http://pubmed.gov/1549490315494903]</ref></SMALL></SMALL></SMALL></SMALL></SMALL>==
 
-->
 
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font></SMALL>


{|
{|
Line 82: Line 76:
</font>
</font>
</div>
</div>


<!--COLLECT ALL THE BOXES BELOW-->
<!--COLLECT ALL THE BOXES BELOW-->
Line 90: Line 82:
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table01" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table01" style="background: #FFFFFF;"
| valign=top |
| valign=top |
 
{| style="float: left; cellpadding=0; cellspacing= 0; width: 450px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cutaneous Anthrax, Adult Patients}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cutaneous Anthrax, Adult Patients}}
|-
|-
Line 98: Line 89:
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]]  500 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  750 mg PO q24h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]]  400 mg PO q24h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]  100 mg PO q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]]  500 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  750 mg PO q24h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]]  400 mg PO q24h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]  100 mg PO q12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen (for Penicillin-Susceptible Strains)
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Clindamycin]] 600 mg PO q8h'''''<BR> OR <BR> ▸ '''''[[Penicillin VK]] 500 mg PO q6h'''''<BR> OR <BR> ▸ '''''[[Amoxicillin]] 1 g PO q8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Clindamycin]] 600 mg PO q8h'''''<BR> OR <BR> ▸ '''''[[Penicillin VK]] 500 mg PO q6h'''''<BR> OR <BR> ▸ '''''[[Amoxicillin]] 1 g PO q8h'''''
Line 106: Line 97:
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table02" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table02" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 450px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cutaneous Anthrax, Pediatric Patients}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cutaneous Anthrax, Pediatric Patients}}
|-
|-
Line 113: Line 104:
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]] 30 mg/kg/day PO q12h, max: 500 mg/dose'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  16 mg/kg/day PO q12h, max: 250 mg/dose (<50 kg)'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  500 mg PO q24h (≥50 kg)'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]  4.4 mg/kg/day PO q12h, max: 100 mg/dose (<45 kg)'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]  100 mg/dose PO q12h (≥45 kg)'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]] 30 mg/kg/day PO q12h, max: 500 mg/dose'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  16 mg/kg/day PO q12h, max: 250 mg/dose (<50 kg)'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  500 mg PO q24h (≥50 kg)'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]  4.4 mg/kg/day PO q12h, max: 100 mg/dose (<45 kg)'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]  100 mg/dose PO q12h (≥45 kg)'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen (for Penicillin-Susceptible Strains)
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Clindamycin]] 30 mg/kg/day PO q8h, max: 600 mg/dose'''''<BR> OR <BR> ▸ '''''[[Penicillin VK]] 50–75 mg/kg/day PO q6–8h'''''<BR> OR <BR> ▸ '''''[[Amoxicillin]] 75 mg/kg/day PO q8h, max: 1 g/dose'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Clindamycin]] 30 mg/kg/day PO q8h, max: 600 mg/dose'''''<BR> OR <BR> ▸ '''''[[Penicillin VK]] 50–75 mg/kg/day PO q6–8h'''''<BR> OR <BR> ▸ '''''[[Amoxicillin]] 75 mg/kg/day PO q8h, max: 1 g/dose'''''
Line 121: Line 112:
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table03" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table03" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 450px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cutaneous Anthrax, Pregnant Patients}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cutaneous Anthrax, Pregnant Patients}}
|-
|-
Line 129: Line 120:
|}
|}
|}
|}


{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table04" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table04" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 450px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Systemic Anthrax with Meningitis, Adult Patients}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Systemic Anthrax with Meningitis, Adult Patients}}
|-
|-
Line 142: Line 132:
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]]  2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[imipenem]]  1 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Doripenem]]  500 mg IV q8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]]  2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Imipenem]]  1 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Doripenem]]  500 mg IV q8h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
Line 148: Line 138:
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]]  600 mg IV q12h'''''<BR> OR <BR> ▸ '''''[[Clindamycin]]  900 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Rifampin]]  600 mg IV q12h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1 g IV q6–8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]]  600 mg IV q12h'''''<BR> OR <BR> ▸ '''''[[Clindamycin]]  900 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Rifampin]]  600 mg IV q12h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1 g IV q6–8h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen (for Penicillin-Susceptible Strains)
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]]  400 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  750 mg IV q24h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]]  400 mg IV q24h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]]  400 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  750 mg IV q24h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]]  400 mg IV q24h'''''
Line 162: Line 152:
|}
|}


{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table05" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 450px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Systemic Anthrax with Meningitis, Pediatric Patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]] 30 mg/kg/day IV q8h, max: 400 mg/dose'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  20 mg/kg/day IV q12h, max: 250 mg/dose (<50 kg)'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  500 mg IV q24h (≥50 kg)'''''<BR> OR <BR> ▸ '''''[[Meropenem]]  60 mg/kg/day IV q12h, max: 2 g/dose'''''<BR> OR <BR> ▸ '''''[[Imipenem/Cilastatin]]  100 mg/kg/day IV q6h, max: 1 g/dose'''''<BR> OR <BR> ▸ '''''[[Vancomycin]]  60 mg/kg/day IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Clindamycin]] 30 mg/kg/day PO q8h, max: 600 mg/dose'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 30 mg/kg/day IV q8h, max: 1 g/dose (<12 yr)'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 30 mg/kg/day IV q12h, max: 600 mg/dose (≥12 yr)'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]  4.4 mg/kg/day IV q12h, max: 100 mg/dose (<45 kg)'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]  200 mg IV x1 then 100 mg IV q12h, max: 200 mg/dose (≥45 kg)'''''<BR> OR <BR> ▸ '''''[[Rifampin]]  20 mg/kg/day IV q12h, max: 300 mg/dose'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] 0.4 MU/kg/day IV q4h, max: 4 MU/dose'''''<BR> OR <BR> ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6h, max: 900 mg/dose'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Clindamycin]] 30 mg/kg/day PO q8h, max: 600 mg/dose'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 30 mg/kg/day IV q8h, max: 1 g/dose (<12 yr)'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 30 mg/kg/day IV q12h, max: 600 mg/dose (≥12 yr)'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]  4.4 mg/kg/day IV q12h, max: 100 mg/dose (<45 kg)'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]  200 mg IV x1 then 100 mg IV q12h, max: 200 mg/dose (≥45 kg)'''''<BR> OR <BR> ▸ '''''[[Rifampin]]  20 mg/kg/day IV q12h, max: 300 mg/dose'''''
|}
|}


{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table06" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 450px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Systemic Anthrax with Meningitis, Pregnant Patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]]  400 mg IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Clindamycin]]  900 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Rifampin]]  600 mg IV q12h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Levofloxacin]]  750 mg IV q24h'''''<BR> OR <BR> ▸ '''''[[Meropenem]]  2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Penicillin G]]  4 MU IV q4h'''''<BR> OR <BR> ▸ '''''[[Ampicillin]]  3 g IV q6h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Clindamycin]]  900 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Rifampin]]  600 mg IV q12h'''''
|}
|}


{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table07" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 450px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Systemic Anthrax Without Meningitis, Adult Patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]]  400 mg q8h'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  750 mg q24h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]]  400 mg PO q24h'''''<BR> OR <BR> ▸ '''''[[Meropenem]]  2 g q8h'''''<BR> OR <BR> ▸ '''''[[Imipenem]]  1 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Doripenem]]  500 mg q8h'''''<BR> OR <BR> ▸ '''''[[Vancomycin]]  60 mg/kg/day IV q8h, trough: 15–20 μg/mL'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Clindamycin]]  900 mg q8h'''''<BR> OR <BR> ▸ '''''[[Linezolid]]  600 mg q12h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]  200 mg x1 then 100 mg IV q12h'''''<BR> OR <BR> ▸ '''''[[Rifampin]]  600 mg q12h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] 4 MU IV q4h'''''<BR> OR <BR> ▸ '''''[[Ampicillin]] 3 g IV q6h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Clindamycin]]  900 mg q8h'''''<BR> OR <BR> ▸ '''''[[Linezolid]]  600 mg q12h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]  200 mg x1 then 100 mg IV q12h'''''<BR> OR <BR> ▸ '''''[[Rifampin]]  600 mg q12h'''''
|}
|}


{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table08" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 450px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Systemic Anthrax Without Meningitis, Pediatric Patients}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]] 30 mg/kg/day IV q8h, max: 400 mg/dose'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  16 mg/kg/day IV q12h, max: 250 mg/dose (<50 kg)'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  500 mg IV q24h (≥50 kg)'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 12 mg/kg/day IV q12h, max: 200 mg/dose (3 mo–2 yr)'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 10 mg/kg/day IV q12h, max: 200 mg/dose (2 yr–5 yr)'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 8 mg/kg/day IV q12h, max: 200 mg/dose (6 yr–11 yr)'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 8 mg/kg/day IV q12h, max: 200 mg/dose (12 yr–17 yr, <45 kg)'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h (12 yr–17 yr, ≥45 kg)'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 120 mg/kg/day IV q8h, max: 2 g/dose'''''<BR> OR <BR> ▸ '''''[[Imipenem/Cilastatin]] 100 mg/kg/day IV q6h, max: 1 g/dose'''''<BR> OR <BR> ▸ '''''[[Doripenem]] 120 mg/kg/day IV q8h, max: 1 g/dose'''''<BR> OR <BR> ▸ '''''[[Vancomycin]]  60 mg/kg/day IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]] 30 mg/kg/day IV q8h, max: 600 mg/dose (<12 yr)'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 30 mg/kg/day IV q12h, max: 600 mg/dose (≥12 yr)'''''<BR> OR <BR> ▸ '''''[[Clindamycin]] 40 mg/kg/day IV q8h, max: 900 mg/dose'''''<BR> OR <BR> ▸ '''''[[Rifampin]] 20 mg/kg/day IV q12h, max: 300 mg/dose'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 100 mg/kg/day IV q6h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]] 30 mg/kg/day IV q8h, max: 400 mg/dose'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  16 mg/kg/day IV q12h, max: 250 mg/dose (<50 kg)'''''<BR> OR <BR> ▸ '''''[[Levofloxacin]]  500 mg IV q24h (≥50 kg)'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 12 mg/kg/day IV q12h, max: 200 mg/dose (3 mo–2 yr)'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 10 mg/kg/day IV q12h, max: 200 mg/dose (2 yr–5 yr)'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 8 mg/kg/day IV q12h, max: 200 mg/dose (6 yr–11 yr)'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 8 mg/kg/day IV q12h, max: 200 mg/dose (12 yr–17 yr, <45 kg)'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h (12 yr–17 yr, ≥45 kg)'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] 0.4 MU/kg/day IV q4h, max: 4 MU/dose'''''<BR> OR <BR> ▸ '''''[[Ampicillin]] 400 mg/kg/day IV q6h, max: 3 g/dose'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]] 30 mg/kg/day IV q8h, max: 600 mg/dose (<12 yr)'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 30 mg/kg/day IV q12h, max: 600 mg/dose (≥12 yr)'''''<BR> OR <BR> ▸ '''''[[Clindamycin]] 40 mg/kg/day IV q8h, max: 900 mg/dose'''''<BR> OR <BR> ▸ '''''[[Rifampin]] 20 mg/kg/day IV q12h, max: 300 mg/dose'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 100 mg/kg/day IV q6h'''''
|-
|}
|}


 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table09" style="background: #FFFFFF;"
 
| valign=top |
 
{| style="float: left; cellpadding=0; cellspacing= 0; width: 450px;"
 
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Systemic Anthrax Without Meningitis, Pregnant Patients}}
 
|-
 
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
 
|-
 
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]]  400 mg IV q8h'''''
 
|-
 
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
 
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Clindamycin]]  900 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Rifampin]]  600 mg IV q12h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Levofloxacin]]  750 mg IV q24h'''''<BR> OR <BR> ▸ '''''[[Meropenem]]  2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Penicillin G]]  4 MU IV q4h'''''<BR> OR <BR> ▸ '''''[[Ampicillin]]  3 g IV q6h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Clindamycin]]  900 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Rifampin]]  600 mg IV q12h'''''
|}
|}


|}
|}

Latest revision as of 18:40, 17 July 2014

▸ Click on the following categories to expand treatment regimens.[1][2][3]

Cutaneous Anthrax Without Systemic Involvement

  ▸  Adult Patients

  ▸  Pediatric Patients

  ▸  Pregnant Patients

Systemic Anthrax with Possible/Confirmed Meningitis

  ▸  Adult Patients

  ▸  Pediatric Patients

  ▸  Pregnant Patients

Systemic Anthrax Without Meningitis

  ▸  Adult Patients

  ▸  Pediatric Patients

  ▸  Pregnant Patients

Cutaneous Anthrax, Adult Patients
Preferred Regimen
Ciprofloxacin 500 mg PO q12h
OR
Levofloxacin 750 mg PO q24h
OR
Moxifloxacin 400 mg PO q24h
OR
Doxycycline 100 mg PO q12h
Alternative Regimen
Clindamycin 600 mg PO q8h
OR
Penicillin VK 500 mg PO q6h
OR
Amoxicillin 1 g PO q8h
Cutaneous Anthrax, Pediatric Patients
Preferred Regimen
Ciprofloxacin 30 mg/kg/day PO q12h, max: 500 mg/dose
OR
Levofloxacin 16 mg/kg/day PO q12h, max: 250 mg/dose (<50 kg)
OR
Levofloxacin 500 mg PO q24h (≥50 kg)
OR
Doxycycline 4.4 mg/kg/day PO q12h, max: 100 mg/dose (<45 kg)
OR
Doxycycline 100 mg/dose PO q12h (≥45 kg)
Alternative Regimen
Clindamycin 30 mg/kg/day PO q8h, max: 600 mg/dose
OR
Penicillin VK 50–75 mg/kg/day PO q6–8h
OR
Amoxicillin 75 mg/kg/day PO q8h, max: 1 g/dose
Cutaneous Anthrax, Pregnant Patients
Preferred Regimen
Ciprofloxacin 500 mg PO q12h
Systemic Anthrax with Meningitis, Adult Patients
Preferred Regimen
Ciprofloxacin 400 mg IV q8h
OR
Levofloxacin 750 mg IV q24h
OR
Moxifloxacin 400 mg IV q24h
PLUS
Meropenem 2 g IV q8h
OR
Imipenem 1 g IV q6h
OR
Doripenem 500 mg IV q8h
PLUS
Linezolid 600 mg IV q12h
OR
Clindamycin 900 mg IV q8h
OR
Rifampin 600 mg IV q12h
OR
Chloramphenicol 1 g IV q6–8h
Alternative Regimen
Ciprofloxacin 400 mg IV q8h
OR
Levofloxacin 750 mg IV q24h
OR
Moxifloxacin 400 mg IV q24h
PLUS
Penicillin G 4 MU IV q4h
OR
Ampicillin 3 g IV q6h
PLUS
Linezolid 600 mg IV q12h
OR
Clindamycin 900 mg IV q8h
OR
Rifampin 600 mg IV q12h
OR
Chloramphenicol 1 g IV q6–8h
Systemic Anthrax with Meningitis, Pediatric Patients
Preferred Regimen
Ciprofloxacin 30 mg/kg/day IV q8h, max: 400 mg/dose
OR
Levofloxacin 20 mg/kg/day IV q12h, max: 250 mg/dose (<50 kg)
OR
Levofloxacin 500 mg IV q24h (≥50 kg)
OR
Meropenem 60 mg/kg/day IV q12h, max: 2 g/dose
OR
Imipenem/Cilastatin 100 mg/kg/day IV q6h, max: 1 g/dose
OR
Vancomycin 60 mg/kg/day IV q8h
PLUS
Clindamycin 30 mg/kg/day PO q8h, max: 600 mg/dose
OR
Linezolid 30 mg/kg/day IV q8h, max: 1 g/dose (<12 yr)
OR
Linezolid 30 mg/kg/day IV q12h, max: 600 mg/dose (≥12 yr)
OR
Doxycycline 4.4 mg/kg/day IV q12h, max: 100 mg/dose (<45 kg)
OR
Doxycycline 200 mg IV x1 then 100 mg IV q12h, max: 200 mg/dose (≥45 kg)
OR
Rifampin 20 mg/kg/day IV q12h, max: 300 mg/dose
Alternative Regimen
Penicillin G 0.4 MU/kg/day IV q4h, max: 4 MU/dose
OR
Ampicillin 200 mg/kg/day IV q6h, max: 900 mg/dose
PLUS
Clindamycin 30 mg/kg/day PO q8h, max: 600 mg/dose
OR
Linezolid 30 mg/kg/day IV q8h, max: 1 g/dose (<12 yr)
OR
Linezolid 30 mg/kg/day IV q12h, max: 600 mg/dose (≥12 yr)
OR
Doxycycline 4.4 mg/kg/day IV q12h, max: 100 mg/dose (<45 kg)
OR
Doxycycline 200 mg IV x1 then 100 mg IV q12h, max: 200 mg/dose (≥45 kg)
OR
Rifampin 20 mg/kg/day IV q12h, max: 300 mg/dose
Systemic Anthrax with Meningitis, Pregnant Patients
Preferred Regimen
Ciprofloxacin 400 mg IV q8h
PLUS
Clindamycin 900 mg IV q8h
OR
Rifampin 600 mg IV q12h
Alternative Regimen
Levofloxacin 750 mg IV q24h
OR
Meropenem 2 g IV q8h
OR
Penicillin G 4 MU IV q4h
OR
Ampicillin 3 g IV q6h
PLUS
Clindamycin 900 mg IV q8h
OR
Rifampin 600 mg IV q12h
Systemic Anthrax Without Meningitis, Adult Patients
Preferred Regimen
Ciprofloxacin 400 mg q8h
OR
Levofloxacin 750 mg q24h
OR
Moxifloxacin 400 mg PO q24h
OR
Meropenem 2 g q8h
OR
Imipenem 1 g IV q6h
OR
Doripenem 500 mg q8h
OR
Vancomycin 60 mg/kg/day IV q8h, trough: 15–20 μg/mL
PLUS
Clindamycin 900 mg q8h
OR
Linezolid 600 mg q12h
OR
Doxycycline 200 mg x1 then 100 mg IV q12h
OR
Rifampin 600 mg q12h
Alternative Regimen
Penicillin G 4 MU IV q4h
OR
Ampicillin 3 g IV q6h
PLUS
Clindamycin 900 mg q8h
OR
Linezolid 600 mg q12h
OR
Doxycycline 200 mg x1 then 100 mg IV q12h
OR
Rifampin 600 mg q12h
Systemic Anthrax Without Meningitis, Pediatric Patients
Preferred Regimen
Ciprofloxacin 30 mg/kg/day IV q8h, max: 400 mg/dose
OR
Levofloxacin 16 mg/kg/day IV q12h, max: 250 mg/dose (<50 kg)
OR
Levofloxacin 500 mg IV q24h (≥50 kg)
OR
Moxifloxacin 12 mg/kg/day IV q12h, max: 200 mg/dose (3 mo–2 yr)
OR
Moxifloxacin 10 mg/kg/day IV q12h, max: 200 mg/dose (2 yr–5 yr)
OR
Moxifloxacin 8 mg/kg/day IV q12h, max: 200 mg/dose (6 yr–11 yr)
OR
Moxifloxacin 8 mg/kg/day IV q12h, max: 200 mg/dose (12 yr–17 yr, <45 kg)
OR
Moxifloxacin 400 mg IV q24h (12 yr–17 yr, ≥45 kg)
PLUS
Meropenem 120 mg/kg/day IV q8h, max: 2 g/dose
OR
Imipenem/Cilastatin 100 mg/kg/day IV q6h, max: 1 g/dose
OR
Doripenem 120 mg/kg/day IV q8h, max: 1 g/dose
OR
Vancomycin 60 mg/kg/day IV q8h
PLUS
Linezolid 30 mg/kg/day IV q8h, max: 600 mg/dose (<12 yr)
OR
Linezolid 30 mg/kg/day IV q12h, max: 600 mg/dose (≥12 yr)
OR
Clindamycin 40 mg/kg/day IV q8h, max: 900 mg/dose
OR
Rifampin 20 mg/kg/day IV q12h, max: 300 mg/dose
OR
Chloramphenicol 100 mg/kg/day IV q6h
Alternative Regimen
Ciprofloxacin 30 mg/kg/day IV q8h, max: 400 mg/dose
OR
Levofloxacin 16 mg/kg/day IV q12h, max: 250 mg/dose (<50 kg)
OR
Levofloxacin 500 mg IV q24h (≥50 kg)
OR
Moxifloxacin 12 mg/kg/day IV q12h, max: 200 mg/dose (3 mo–2 yr)
OR
Moxifloxacin 10 mg/kg/day IV q12h, max: 200 mg/dose (2 yr–5 yr)
OR
Moxifloxacin 8 mg/kg/day IV q12h, max: 200 mg/dose (6 yr–11 yr)
OR
Moxifloxacin 8 mg/kg/day IV q12h, max: 200 mg/dose (12 yr–17 yr, <45 kg)
OR
Moxifloxacin 400 mg IV q24h (12 yr–17 yr, ≥45 kg)
PLUS
Penicillin G 0.4 MU/kg/day IV q4h, max: 4 MU/dose
OR
Ampicillin 400 mg/kg/day IV q6h, max: 3 g/dose
PLUS
Linezolid 30 mg/kg/day IV q8h, max: 600 mg/dose (<12 yr)
OR
Linezolid 30 mg/kg/day IV q12h, max: 600 mg/dose (≥12 yr)
OR
Clindamycin 40 mg/kg/day IV q8h, max: 900 mg/dose
OR
Rifampin 20 mg/kg/day IV q12h, max: 300 mg/dose
OR
Chloramphenicol 100 mg/kg/day IV q6h
Systemic Anthrax Without Meningitis, Pregnant Patients
Preferred Regimen
Ciprofloxacin 400 mg IV q8h
PLUS
Clindamycin 900 mg IV q8h
OR
Rifampin 600 mg IV q12h
Alternative Regimen
Levofloxacin 750 mg IV q24h
OR
Meropenem 2 g IV q8h
OR
Penicillin G 4 MU IV q4h
OR
Ampicillin 3 g IV q6h
PLUS
Clindamycin 900 mg IV q8h
OR
Rifampin 600 mg IV q12h

References

  1. Hendricks, Katherine A. (2014-02). "Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults". Emerging Infectious Diseases. 20 (2). doi:10.3201/eid2002.130687. ISSN 1080-6059. PMC 3901462. PMID 24447897. Unknown parameter |coauthors= ignored (help); Check date values in: |date= (help)
  2. Bradley, John S. (2014-04-28). "Pediatric Anthrax Clinical Management". Pediatrics. doi:10.1542/peds.2014-0563. ISSN 1098-4275. PMID 24777226. Unknown parameter |coauthors= ignored (help)
  3. Meaney-Delman, Dana (2014-02). "Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women". Emerging Infectious Diseases. 20 (2). doi:10.3201/eid2002.130611. ISSN 1080-6059. PMC 3901460. PMID 24457117. Unknown parameter |coauthors= ignored (help); Check date values in: |date= (help)